Historically, Pneumocystis pneumonia (PCP) and other opportunistic pneumonias have been major causes of morbidity and mortality among human immunodeficiency virus (HIV)-infected persons. The long-term objective of this study is to create an international, multi-center, longitudinal cohort that reflects the HIV/AIDS epidemic in Africa (Uganda), Europe (United Kingdom), and North America (United States) to study PCP and opportunistic pneumonias. We propose a prospective, longitudinal cohort study that will enroll and follow 600-750 HIV-infected patients per year who are admitted with pneumonia to Mulago Hospital (Kampala, Uganda);University College London Hospitals (London, UK);and San Francisco General Hospital (San Francisco, CA, US). Patients will be followed throughout their hospitalization and every 6 months after hospital discharge to determine the frequency and mortality of PCP and HIV-associated opportunistic pneumonias. We will also collect serum, oropharyngeal wash, Scope mouthwash, sputum, and bronchoscopy specimens to address hypothesis-driven research questions. We propose the following aims:
Aim 1 : To determine the frequency and mortality of HIV-associated opportunistic pneumonias in an international, multi-center, longitudinal cohort and to test the hypothesis that PCP is associated with increased mortality.
Aim 2 : To estimate the sensitivity and specificity of molecular tools for PCP and tuberculosis (TB) diagnosis and to test the hypotheses that 60-second oropharyngeal washing (OPW, gargle) specimens combined with polymerase chain reaction (PCR) assays are sensitive tests to diagnose PCP and TB.
Aim 3 : To test the hypothesis that Pneumocystis dihydropteroate synthase (DHPS) gene mutations are associated with an increased mortality and to explore potential mechanisms.
Aim 4 : To characterize the predominant Pneumocystis Msg-C variant recognized by subjects at each site, to examine systemic (serum) and local (BAL) antibody responses, and to test the hypothesis that the level of antibodies to the predominant variant is correlated with PCP status. In the future, we plan to expand the scientific focus to include other pneumonias, such as TB and bacterial pneumonia that are beyond the scope of this proposal, Relevance to public health: Pneumocystis pneumonia (PCP) is a significant cause of illness and death among human immunodeficiency virus (HIV)-infected and other immunocompromised persons. This study will examine newer methods to diagnose PCP and will determine whether Pneumocystis is becoming resistant to medications that are used to treat PCP. The development of rapid, non-invasive methods to diagnose PCP would be a significant advance, while the demonstration of drug resistance would have serious implications, given the limited PCP treatment medications currently available.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL090335-05
Application #
8102087
Study Section
Special Emphasis Panel (ZHL1-CSR-Z (S1))
Program Officer
Peavy, Hannah H
Project Start
2007-09-28
Project End
2014-06-30
Budget Start
2011-07-01
Budget End
2014-06-30
Support Year
5
Fiscal Year
2011
Total Cost
$743,443
Indirect Cost
Name
University of California San Francisco
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Shenoy, Meera K; Iwai, Shoko; Lin, Din L et al. (2017) Immune Response and Mortality Risk Relate to Distinct Lung Microbiomes in Patients with HIV and Pneumonia. Am J Respir Crit Care Med 195:104-114
Shete, Priya B; Ravindran, Resmi; Chang, Emily et al. (2017) Evaluation of antibody responses to panels of M. tuberculosis antigens as a screening tool for active tuberculosis in Uganda. PLoS One 12:e0180122
Ponce, Carolina A; Chabé, Magali; George, Claudio et al. (2017) High Prevalence of Pneumocystis jirovecii Dihydropteroate Synthase Gene Mutations in Patients with a First Episode of Pneumocystis Pneumonia in Santiago, Chile, and Clinical Response to Trimethoprim-Sulfamethoxazole Therapy. Antimicrob Agents Chemother 61:
Wang, Richard J; Miller, Robert F; Huang, Laurence (2017) Approach to Fungal Infections in Human Immunodeficiency Virus-Infected Individuals: Pneumocystis and Beyond. Clin Chest Med 38:465-477
Meyer, Amanda J; Atuheire, Collins; Worodria, William et al. (2017) Sputum quality and diagnostic performance of GeneXpert MTB/RIF among smear-negative adults with presumed tuberculosis in Uganda. PLoS One 12:e0180572
Blount, Robert J; Daly, Kieran R; Fong, Serena et al. (2017) Effects of clinical and environmental factors on bronchoalveolar antibody responses to Pneumocystis jirovecii: A prospective cohort study of HIV+ patients. PLoS One 12:e0180212
Walter, Nicholas D; de Jong, Bouke C; Garcia, Benjamin J et al. (2016) Adaptation of Mycobacterium tuberculosis to Impaired Host Immunity in HIV-Infected Patients. J Infect Dis 214:1205-11
Katagira, Winceslaus; Walter, Nicholas D; Den Boon, Saskia et al. (2016) Empiric TB Treatment of Severely Ill Patients With HIV and Presumed Pulmonary TB Improves Survival. J Acquir Immune Defic Syndr 72:297-303
Auld, Elizabeth; Lin, Jue; Chang, Emily et al. (2016) HIV Infection Is Associated with Shortened Telomere Length in Ugandans with Suspected Tuberculosis. PLoS One 11:e0163153
Leader, Joseph K; Crothers, Kristina; Huang, Laurence et al. (2016) Risk Factors Associated With Quantitative Evidence of Lung Emphysema and Fibrosis in an HIV-Infected Cohort. J Acquir Immune Defic Syndr 71:420-7

Showing the most recent 10 out of 85 publications